The ACT study is a multi-site, randomized controlled trial to reduce neonatal mortality by improving identification of women at risk of preterm delivery and increasing the use of antenatal corticosteroids. A multi-faceted intervention among health care providers will be tested in six middle and low-income countries.
Primary Manuscript
Althabe F, Belizán JM, McClure EM, Hemingway-Foday J, Berrueta M, Mazzoni A, Ciganda A, Goudar SS, Kodkany BS, Mahantshetti NS, Dhaded SM, Katageri GM, Metgud MC, Joshi AM, Bellad MB, Honnungar NV, Derman RJ, Saleem S, Pasha O, Ali S, Hasnain F, Goldenberg RL, Esamai F, Nyongesa P, Ayunga S, Liechty EA, Garces AL, Figueroa L, Hambidge KM, Krebs NF, Patel A, Bhandarkar A, Waikar M, Hibberd PL, Chomba E, Carlo WA, Mwiche A, Chiwila M, Manasyan A, Pineda S, Meleth S, Thorsten V, Stolka K, Wallace DD, Koso-Thomas M,Jobe AH, Buekens PM. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. Lancet. 2015 Feb 14;385(9968):629-39. doi: 10.1016/S0140-6736(14)61651-2. Epub 2014 Oct 15. PMCID: PMC4420619 PMID: 25458726
Participating Institutions
- Tulane School of Public Health and Tropical Medicine
- JN Medical College, Belgaum, India
- Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina
- University of Alabama at Birmingham
- Aga Khan University, Karachi, Pakistan
- University Teaching Hospital, Lusaka, Zambia
- Massachusetts General Hospital
- University of Colorado Denver
- Lata Medical Research Foundation, Nagpur, India
- Instituto de Nutrición de Centro América y Panamá
- Christiana Care
- Moi University, Eldoret, Kenya
- RTI International